NM_198185 ACCESSION:NM_198185 NID: gi 38044105 ref NM_198185.1 Homo sapiens oviductin protease (OVTN), mRNA Length = 1695


Score = 619 bits (1580), Expect = e-175Identities = 300/302 (99%), Positives = 300/302 (99%), Gaps = 0/302 (0%) Frame = +1

- Query: 5 MLISRNKLILLLGIVFFERGKSAALSLPKAPSCGQSLVKVQPWNYFNIFSRILGGSQVEK 62 MLISRNKLILLLGIVFFERGKSA LSLPKAPSCGQSLVKVQPWNYFNIFSRILGGSQVEK
- Sbjct: 1 MLISRNKLILLLGIVFFERGKSATLSLPKAPSCGQSLVKVQPWNYFNIFSRILGGSQVEK 180
- Query: 63 GSYPWQVSLKQRQKHICGGSIVSPQWVITAAHCIANRNIVSTLNVTAGEYDLSQTDPGEQ 122 GSYPWQVSLKQRQKHICGGSIVSPQWVITAAHCIANRNIVSTLNVTAGEYDLSQTDPGEQ
- Sbjct: 181 GSYPWQVSLKQRQKHICGGSIVSPQWVITAAHCIANRNIVSTLNVTAGEYDLSQTDPGEQ 360
- Query: 123 TLTIETVIIHPHFSTKKPMDYDIALLKMAGAFQFGHFVGPICLPELREQFEAGFICTTAG 182 TLTIETVIIHPHFSTKKPMDYDIALLKMAGAFQFGHFVGPICLPELREQFEAGFICTTAG
- Sbjct: 361 TLTIETVIIHPHFSTKKPMDYDIALLKMAGAFQFGHFVGPICLPELREQFEAGFICTTAG 540
- Query: 183 WGRLTEGGVLSQVLQEVNLPILTWEECVAALLTLKRPISGKTFLCTGFPDGGRDACQGDS 242 WGRLTEGGVLSQVLQEVNLPILTWEECVAALLTLKRPISGKTFLCTGFPDGGRDACQGDS
- Sbjct: 541 WGRLTEGGVLSQVLQEVNLPILTWEECVAALLTLKRPISGKTFLCTGFPDGGRDACQGDS 720
- Query: 243 GGSLMCRNKKGAWTLAGVTSWGLGCGRGWRNNVRKSDQGSPGIFTDISKVLSWIHEHIQT 302 GGSLMCRNKKGAWTLAGVTSWGLGCGRGWRNNVRKSDQGSPGIFTDISKVL WIHEHIQT
- Sbjct: 721 GGSLMCRNKKGAWTLAGVTSWGLGCGRGWRNNVRKSDQGSPGIFTDISKVLPWIHEHIQT 900

Query: 303 GN 304

GN

Sbict: 901 GN 906



```
70..1692
     mat_peptide
                     /gene="OVTN"
                     /product="oviductin protease"
     misc_feature
                     151..882
                     /gene="OVTN"
                     /note="Tryp_SPc; Region: Trypsin-like serine protease"
                     /db_xref="CDD:smart00020"
                     976..1254
     misc_feature
                     /gene="OVTN"
                     /note="CUB; Region: CUB domain"
                     /db_xref="CDD:pfam00431"
     misc_feature
                     1321..1617
                     /gene="OVTN"
                     /note="CUB; Region: CUB domain"
                     /db_xref="CDD:pfam00431"
ORIGIN
       1 atgcttataa gcaggaacaa gctgatttta ctactaggaa tagtcttttt tgaacgaggt
       61 aaatctgcaa ctctttcgct ccccaaagct cccagttgtg ggcagagtct ggttaaggta
      121 cagccttgga attattttaa cattttcagt cgcattcttg gaggaagcca agtggagaag
      181 gqttcctatc cctggcaggt atctctgaaa caaaggcaga agcatatttg tggaggaagc
      241 atcqtctcac cacagtgggt gatcacggcg gctcactgca ttgcaaacag aaacattgtg
      301 tctactttga atgttactgc tggagagtat gacttaagcc agacagaccc aggagagcaa
      361 actctcacta ttgaaactgt catcatacat ccacatttct ccaccaagaa accaatggac
      421 tatgatattg cccttttgaa gatggctgga gccttccaat ttggccactt tgtggggccc
      481 atatgtcttc cagagctgcg ggagcaattt gaggctggtt ttatttgtac aactgcaggc
      541 tggggccgct taactgaagg tggcgtcctc tcacaagtct tgcaggaagt gaatctgcct
      601 attttgacct gggaagagtg tgtggcagct ctgttaacac taaagaggcc catcagtggg
      661 aagacettte tttgcacagg tttteetgat ggagggagag acgeatgtea gggagattea
      721 ggaggttcac tcatgtgccg gaataagaaa ggggcctgga ctctggctgg tgtgacttcc
      781 tggggtttgg gctgtggtcg aggctggaga aacaatgtga ggaaaagtga tcaaggatcc
      841 cctgggatct tcacagacat tagtaaagtg cttccctgga tccacgaaca catccaaact
      901 ggtaatcgga gaaagagctc cagagcctgg tgcagtgagc aggatgtcat agtcagcggg
      961 gctgagggga agctgcactt cccagaaagc ctccacctat attatgagag caagcaacgg
     1021 tgtgtctgga ccctgctggt accagaggaa atgcatgtgt tgctcagttt ttcccaccta
     1081 gatgttgagt cttgtcacca cagttacctg tcaatgtatt ctttagaaga cagacccatt
     1141 ggaaaatttt gtggagaaag cctcccttca tccattctta ttggctctaa ttctctaagg
     1201 ctgaaattcg tctctgatgc cacagattat gcagctgggt ttaatcttac ctataaagct
     1261 cttaaaccaa actacattcc tgattcaggt tgcagttact taactgtcct ttttgaagaa
     1321 ggtctcatac agagtctaaa ctatcctgaa aactacagtg acaaggctaa ctgtgactgg
     1381 atttttcaag cctccaaaca tcacctaatt aagctttcat ttcagagtct ggaaatagaa
     1441 gaaagtggag actgcacttc cgactatgtg acagtgcaca gcgatgtaga aaggaagaag
     1501 gaaatagctc ggctgtgtgg ctatgatgtc cccaccctg tgctgagccc ctccagcatc
     1561 atgctcatca gcttccaatc agatgaaaac gggacctgca ggggctttca ggctacagtc
     1621 tccttcattc ctaaagcagg taagaagata gagttaccaa ctctttggtt cccagttcta
     1681 atccttgtga tgtga
//
```

<u>Disclaimer</u> | <u>Write to the Help Desk</u> <u>NCBI | NLM | NIH</u>

Nov 3 2003 07:26:36

Homo sapiens. Human CVSP14 full length cDNA. PA:CORVAS INT INC. PN:WO200277263-A2. gsn
Length = 1035

Score = 628 bits (1603), Expect = e-179Identities = 305/306 (99%), Positives = 306/306 (100%), Gaps = 0/306 (0%) Frame = +1

Query: 1 MSLKMLISRNKLILLLGIVFFERGKSAALSLPKAPSCGQSLVKVQPWNYFNIFSRILGGS 58 MSLKMLISRNKLILLLGIVFFE+GKSAALSLPKAPSCGQSLVKVQPWNYFNIFSRILGGS

Sbjct: 115 MSLKMLISRNKLILLLGIVFFEQGKSAALSLPKAPSCGQSLVKVQPWNYFNIFSRILGGS 294

Query: 59 QVEKGSYPWQVSLKQRQKHICGGSIVSPQWVITAAHCIANRNIVSTLNVTAGEYDLSQTD 118 OVEKGSYPWOVSLKOROKHICGGSIVSPQWVITAAHCIANRNIVSTLNVTAGEYDLSQTD

Sbjct: 295 QVEKGSYPWQVSLKQRQKHICGGSIVSPQWVITAAHCIANRNIVSTLNVTAGEYDLSQTD 474

Query: 119 PGEQTLTIETVIIHPHFSTKKPMDYDIALLKMAGAFQFGHFVGPICLPELREQFEAGFIC 178
PGEOTLTIETVIIHPHFSTKKPMDYDIALLKMAGAFQFGHFVGPICLPELREQFEAGFIC

Sbjct: 475 PGEQTLTIETVIIHPHFSTKKPMDYDIALLKMAGAFQFGHFVGPICLPELREQFEAGFIC 654

Query: 179 TTAGWGRLTEGGVLSQVLQEVNLPILTWEECVAALLTLKRPISGKTFLCTGFPDGGRDAC 238
TTAGWGRLTEGGVLSQVLQEVNLPILTWEECVAALLTLKRPISGKTFLCTGFPDGGRDAC

Sbjct: 655 TTAGWGRLTEGGVLSQVLQEVNLPILTWEECVAALLTLKRPISGKTFLCTGFPDGGRDAC 834

Query: 239 QGDSGGSLMCRNKKGAWTLAGVTSWGLGCGRGWRNNVRKSDQGSPGIFTDISKVLSWIHE 298 QGDSGGSLMCRNKKGAWTLAGVTSWGLGCGRGWRNNVRKSDQGSPGIFTDISKVLSWIHE


Sbjct: 835 QGDSGGSLMCRNKKGAWTLAGVTSWGLGCGRGWRNNVRKSDQGSPGIFTDISKVLSWIHE 1014

Query: 299 HIQTGN 304

HIOTGN

Sbjct: 1015HIQTGN 1032





Français

1 of 2

View Images

PUBLISHED INTERNATIONAL APPLICATION

(11)	WO 02/077263	(13)	A2					
(21)	PCT/US02/09039	PCT/US02/09039						
(22)	20 March 2002 (20.03.2002)							
(25)	ENG	(26)	ENG					
(31)	60/278,166	(32)	22 March 2001 (22.03.2001)	US				
(43)	03 October 2002 (03.10.2002)							
$(51)^7$	C12Q							
(54)	NUCLEIC ACID MOLECULES ENCODING SERINE PROTEASE CVSP14, THE ENCODED POLYPEPTIDES AND METHODS BASED THEREON							
(61)	US 60/278,166	(CIP)						
	Filed on 22 March 2	2001 (22	.03.2001)					
(71)	CORVAS INTERNATIONAL, INC. 3030 Science Park Road, San Diego, CA 92121; (US). [US/US].(for all designated States except US)							
(72)(75)]. YEH,	5 Cedarcrest Way, San Diego, CA Jiunn-Chern 11629 Wetsview Parw [US/—].	ay,				
(74)	SEIDMAN, Stéphanie, L. Heller Ehrman White & McAuliffe LLP, 4350 La Jolla Village Drive, San Diego, CA 92122-1246; (US).							
(81)								
	CN, CO, CR, CU, CZ, GE, GH, GM, HR, HU LK, LR, LS, LT, LU, L NO, NZ, OM, PH, PL,	DE, DK , ID, IL, .V, MA, PT, RO	Z, BA, BB, BG, BR, BY, BZ, CA, CI , DM, DZ, EC, EE, ES, FI, GB, GD, IN, IS, JP, KE, KG, KP, KR, KZ, LO MD, MG, MK, MN, MW, MX, MZ , RU, SD, SE, SG, SI, SK, SL, TJ, TN UZ, VN, YU, ZA, ZM, ZW	C,				
(84)	•							
	ZW), Eurasian patent (European patent (AT, I	AM, AZ BE, CH,	LS, MW, MZ, SD, SL, SZ, TZ, UG, Z Z, BY, KG, KZ, MD, RU, TJ, TM), CY, DE, DK, ES, FI, FR, GB, GR, D OAPI patent (BF, BJ, CF, CG, CI, C	E,				

GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG)

For information on time limits for entry into the national phase please click here

Published

without international search report and to be republished upon receipt of that report

Declaration under Rule 4.17

as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii)) for the following designations AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW, ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG)


as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii)) for the following designations AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW, ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG)

No Image Available.

Abstract

Provided herein are polypeptides designated CVSP14 polypeptides that exhibit protease activity as a single chain or as an activated two chain form. Methods using the polypeptides to identify compounds that modulate the protease activity thereof are provides. The polypeptides also serve as tumor markers.





Français

1 of 2

Homo sapiens. Human protease PRTS-20 cDNA sequence. PA:INCYTE GENOMICS INC. PN:WO200198468-A2. gsn
Length = 1262

Score = 628 bits (1603), Expect = e-179Identities = 305/306 (99%), Positives = 305/306 (99%), Gaps = 0/306 (0%) Frame = +3

Query: 1 MSLKMLISRNKLILLLGIVFFERGKSAALSLPKAPSCGQSLVKVQPWNYFNIFSRILGGS 58 MSLKMLISRNKLILLLGIVFFERGKSA LSLPKAPSCGQSLVKVQPWNYFNIFSRILGGS

Sbjct: 165 MSLKMLISRNKLILLLGIVFFERGKSATLSLPKAPSCGQSLVKVQPWNYFNIFSRILGGS 344

Query: 59 QVEKGSYPWQVSLKQRQKHICGGSIVSPQWVITAAHCIANRNIVSTLNVTAGEYDLSQTD 118 QVEKGSYPWQVSLKQRQKHICGGSIVSPQWVITAAHCIANRNIVSTLNVTAGEYDLSQTD

Sbjct: 345 QVEKGSYPWQVSLKQRQKHICGGSIVSPQWVITAAHCIANRNIVSTLNVTAGEYDLSQTD 524

Query: 119 PGEQTLTIETVIIHPHFSTKKPMDYDIALLKMAGAFQFGHFVGPICLPELREQFEAGFIC 178 PGEQTLTIETVIIHPHFSTKKPMDYDIALLKMAGAFQFGHFVGPICLPELREQFEAGFIC

Sbjct: 525 PGEQTLTIETVIIHPHFSTKKPMDYDIALLKMAGAFQFGHFVGPICLPELREQFEAGFIC 704

Query: 179 TTAGWGRLTEGGVLSQVLQEVNLPILTWEECVAALLTLKRPISGKTFLCTGFPDGGRDAC 238 TTAGWGRLTEGGVLSQVLQEVNLPILTWEECVAALLTLKRPISGKTFLCTGFPDGGRDAC

Sbjct: 705 TTAGWGRLTEGGVLSQVLQEVNLPILTWEECVAALLTLKRPISGKTFLCTGFPDGGRDAC 884


Query: 239 QGDSGGSLMCRNKKGAWTLAGVTSWGLGCGRGWRNNVRKSDQGSPGIFTDISKVLSWIHE 298 QGDSGGSLMCRNKKGAWTLAGVTSWGLGCGRGWRNNVRKSDQGSPGIFTDISKVLSWIHE

Sbjct: 885 QGDSGGSLMCRNKKGAWTLAGVTSWGLGCGRGWRNNVRKSDQGSPGIFTDISKVLSWIHE 1064

Query: 299 HIQTGN 304

HIOTGN

Sbjct: 1065HIQTGN 1082



Français

1 of 1

View Images

PUBLISHED INTERNATIONAL APPLICATION

(11)	WO 01/98468	(13)	A2			
(21)	PCT/US01/19178					
(22)	13 June 2001 (13.06.2001)					
(25)	ENG	(26)	ENG			
(31)	60/212,336	(32)	16 June 2000 (16.06.2000)	US		
(31)	60/213,955	(32)	22 June 2000 (22.06.2000)	US		
(31)	60/215,396	(32)	29 June 2000 (29.06.2000)	US		
(31)	60/216,821	(32)	07 July 2000 (07.07.2000)	US		
(31)	60/218,946	(32)	14 July 2000 (14.07.2000)	US		
(43)	27 December 2001 (27.12.2001)					
$(51)^7$	C12N 9/00					
(54)	PROTEASES					
(71)	INCUTE CENOMICS INC 3160 Porter Drive Palo Alto CA 94304					

- (71) INCYTE GENOMICS, INC. 3160 Porter Drive, Palo Alto, CA 94304; (US). [US/US].(for all designated States except US)
- YUE, Henry 826 Lois Avenue, Sunnyvale, CA 94087; (US) (72)(75)[US/US]. ELLIOTT, Vicki, S. 3770 Polton Place Way, San Jose, CA 95121; (US) [US/US].GANDHI, Ameena, R. 837 Roble Avenue, #1, Menlo Park, CA 94025; (US) [US/US].LAL, Preeti P.O. Box 5142, Santa Clara, CA 95056; (US) [US/IN].AU-YOUNG, Janice 233 Golden Eagle Lane, Brisbane, CA 94005; (US) [US/US]. TRIBOULEY, Catherine, M. 1121 Tennessee Street, #5, San Francisco, CA 94107; (US) [US/FR]. DELEGEANE, Angelo, M. 594 Angus Drive, Milpitas, CA 95035; (US) [US/US].BAUGHN, Mariah, R. 14244 Santiago Road, San Leandro, CA 94577; (US) [US/US].NGUYEN, Danniel, B. 1403 Ridgewood Drive, San Jose, CA 95118; (US) [US/US].LEE, Ernestine, A. 624 Kains Street, Albany, CA 94706; (US) [US/US].HAFALIA, April 2227 Calle de Primavera, Santa Clara, CA 95054; (US) [US/US].KHAN, Farrah, A. 3617 Central Road #102, Glenview, IL 60025; (US) [US/IN].WALIA, Narinder, K. 890 Davis Street #205, San Leandro, CA 94577; (US) [US/US]. YAO, Monique, G. 111 Frederick Court, Mountain View, CA 94043; (US) [US/US].LU, Dyung, Aina, M. 233 Cov Drive, San Jose, CA 95123; (US) [US/US].PATTERSON, Chandra 490 Sherwood Way #1, Menlo Park, CA 94025; (US) [US/US]. TANG, Y., Tom 4230 Ranwick Court, San Jose, CA 95118; (US) [US/US]. WALSH, Roderick, T. 8 Boundary Court, St. Lawrence

Road, Canterbury, Kent CT1 3EZ; (GB) [US/IE].AZIMZAI, Yalda 5518 Boulder Canyon Drive, Castro Valley, CA 94552; (US) [US/US].LU, Yan 3885 Corrina Way, Palo Alto, CA 94303; (US) [US/CN].RAMKUMAR, Jayalaxmi 34359 Maybird Circle, Fremont, CA 94555; (US) [US/IN].XU, Yuming 1739 Walnut Drive, Mountain View, CA 94040; (US) [US/US].REDDY, Roopa 1233 W. McKinley Avenue #3, Sunnyvale, CA 94086; (US) [US/IN].DAS, Debopriya 1179 Bonita Avenue, Apt. 3, Mountain View, CA 94040; (US) [US/IN].KEARNEY, Liam 50 Woodside Avenue, San Francisco, CA 94127; (US) [US/IE].KALLICK, Deborah, A. 900 Olive Street, Menlo Park, CA 94025; (US) [US/US].

- (74) **HAMLET-COX, Diana** Incyte Genomics, Inc., 3160 Porter Drive, Palo Alto, CA 94304; (US).
- (81)

 AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW

(84)

ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG)


For information on time limits for entry into the national phase please click here Published without international search report and to be republished

upon receipt of that report

No Image Available.

Abstract

The invention provides human proteases (PRTS) and polynucleotides which identify and encode PRTS. The invention also provides expression vectors, host cells, antibodies, agonists, and antagonists. The invention also provides methods for diagnosing, treating, or preventing disorders associated with aberrant expression of PRTS.



Français

1 of 1

characterize the protein. A starting material that can only be used to produce a final product does not have a substantial asserted utility in those instances where the final product is not supported by a specific and substantial utility. In this case none of the proteins that are to be produced as final products resulting from processes involving the claimed cDNA have asserted or identified specific and substantial utilities. The research contemplated by Applicants to characterize potential protein products, especially their biological activities, does not constitute a specific and substantial utility. Identifying and studying the properties of the protein itself or the mechanisms in which the protein is involved does not define a "real world" context of use. Note, because the claimed invention is not supported by a specific and substantial asserted utility for the reasons set forth above, credibility has not been assessed. Neither the specification as filed nor any art of record discloses or suggests any property or activity for the cDNA compounds such that another non-asserted utility would be well established for the compounds.

Claim 1 is also rejected under 35 U.S.C. § 112, first paragraph. Specifically, since the claimed invention is not supported by either a specific and substantial asserted utility or a well established utility for the reasons set forth above, one skilled in the art would not know how to use the claimed invention.

Example 10: <u>DNA Fragment encoding a Full Open Reading Frame</u> (ORF)

Specification: The specification discloses that a cDNA library was prepared from human kidney epithelial cells and 5000 members of this library were

sequenced and open reading frames were identified. The specification discloses a Table that indicates that one member of the library having SEQ ID NO: 2 has a high level of homology to a DNA ligase. The specification teaches that this complete ORF (SEQ ID NO: 2) encodes SEQ ID NO: 3. An alignment of SEQ ID NO: 3 with known amino acid sequences of DNA ligases indicates that there is a high level of sequence conservation between the various known ligases. The overall level of sequence similarity between SEQ ID NO: 3 and the consensus sequence of the known DNA ligases that are presented in the specification reveals a similarity score of 95%. A search of the prior art confirms that SEQ ID NO: 2 has high homology to DNA Ligase encoding nucleic acids and that the next highest level of homology is to alpha-actin. However, the latter homology is only 50%. Based on the sequence homologies, the specification asserts that SEQ ID NO: 2 encodes a DNA ligase.

Claim 1: An isolated and purified nucleic acid comprising SEQ ID NO: 2.

Analysis: The following analysis includes the questions that need to be asked according to the guidelines and the answers to those questions based on the above facts:

1) Based on the record, is there a "well established utility" for the claimed invention? Based upon applicant's disclosure and the results of the PTO search, there is no reason to doubt the assertion that SEQ ID NO: 2 encodes a DNA ligase. Further, DNA ligases have a well-established use in the molecular biology art based on this class of protein's ability to ligate DNA. Consequently the answer to the question is yes.

Note that if there is a well-established utility already associated with the claimed invention, the utility need not be asserted in the specification as filed. In order to determine whether the claimed invention has a well-established utility the examiner must determine that the invention has a specific, substantial and credible utility that would have been readily apparent to one of skill in the art. In this case SEQ ID NO: 2 was shown to encode a DNA ligase that the artisan would have recognized as having a specific, substantial and credible utility based on its enzymatic activity.

Thus, the conclusion reached from this analysis is that a 35 U.S.C. § 101 rejection and a 35 U.S.C. § 112, first paragraph, utility rejection should not be made.

Example 11: Animals with Uncharacterized Human Genes

Specification: Kidney cells from a patient with Polycystic Kidney (PCK) Disease have been used to make a cDNA library. From this library 8000 nucleotide "fragments" have been sequenced but not yet used to express proteins in a transformed host cell nor have they been characterized in any other way. The 50 longest fragments, SEQ ID NO: 1-50, respectively, have been used to make transgenic mice. None of the 50 lines of mice have developed Polycystic Kidney Disease to date. The asserted utility is the use of the mice to research human genes from diseased human kidneys. The disease is inheritable, but chromosomal loci have not yet been identified. Neither the absence or presence of a specific protein has been identified with the disease condition.

E Score (bits) Value Sequences producing significant alignments: 391 e-106 AC104237.2.1.164732 >AC104237.2.1.164732 Length = 164732Score = 391 bits (197), Expect = e-106 Identities = 200/201 (99%) Strand = Plus / Plus cagggagattcaggaggttcactcatgtgccggaataagaaaggggcctggactctggct 780 Ouery: 721 Sbjct: 51293 cagggagattcaggaggttcactcatgtgccggaataagaaaggggcctggactctggct 51352 ggtgtgacttcctggggtttgggctgtggtcgaggctggagaaacaatgtgaggaaaagt 840 Query: 781 Sbjct: 51353 ggtgtgacttcctggggtttgggctgtggtcgaggctggagaaacaatgtgaggaaaagt 51412 gatcaaggatcccctgggatcttcacagacattagtaaagtgctttcctggatccacgaa 900 Query: 841 Sbjct: 51413 gatcaaggatcccctgggatcttcacagacattagtaaagtgcttccctggatccacgaa 51472 cacatccaaactggtaactaa 921 Query: 901 Sbjct: 51473 cacatccaaactggtaactaa 51493 Score = 349 bits (176), Expect = 1e-93 Identities = 176/176 (100%) Strand = Plus / Plus Query: 301 ccaggagagcaaactctcactattgaaactgtcatcatacatccacatttctccaccaag 420 Query: 361 Sbjct: 49510 ccaggagagcaaactctcactattgaaactgtcatcatacatccacatttctccaccaag 49569 aaaccaatggactatgatattgcccttttgaagatggctggagccttccaatttgg 476 Ouery: 421 Sbjct: 49570 aaaccaatggactatgatattgcccttttgaagatggctggagccttccaatttgg 49625

4

Score = 308 bits (155), Expect = 5e-81
Identities = 155/155 (100%)
Strand = Plus / Plus

Query: 570 aggtggcgtcctctcacaagtcttgcaggaagtgaatctgcctattttgacctgggaaga 629

Query: 690 aggttttcctgatggagggagagacgcatgtcagg 724

Sbjct: 50424 aggttttcctgatggagggagagacgcatgtcagg 50458

Score = 226 bits (114), Expect = 2e-56

Identities = 114/114 (100%)

Strand = Plus / Plus

Query: 99 agctcccagttgtgggcagagtctggttaaggtacagccttggaattattttaacatttt 158

Sbjct: 47105 agctcccagttgtgggcagagtctggttaaggtacagccttggaattattttaacatttt 47164

Query: 159 cagtcgcattcttggaggaagccaagtggagaagggttcctatccctggcaggt 212

Sbjct: 47165 cagtcgcattcttggaggaagccaagtggagaagggttcctatccctggcaggt 47218

Score = 197 bits (99), Expect = 1e-47

Identities = 99/99 (100%)

Strand = Plus / Plus

Query: 475 ggccactttgtggggcccatatgtcttccagagctgcgggagcaatttgaggctggtttt 534

Sbjct: 49969 ggccactttgtggggcccatatgtcttccagagctgcgggagcaatttgaggctggtttt 50028

Query: 535 atttgtacaactgcaggctggggccgcttaactgaaggt 573

Sbjct: 50029 atttgtacaactgcaggctggggccgcttaactgaaggt 50067

Score = 191 bits (96), Expect = 9e-46
Identities = 98/100 (98%)
Strand = Plus / Plus

Query: 1 atgagtctcaaaatgcttataagcaggaacaagctgattttactactaggaatagtcttt 60

Sbjct: 45375 atgagtctcaaaatgcttataagcaggaacaagctgattttactactaggaatagtcttt 45434

Query: 61 tttgaacraggtaaatctgcarctctttcgctccccaaag 100

Sbjct: 45435 tttgaacgaggtaaatctgcaactctttcgctccccaaag 45474

Score = 187 bits (94), Expect = 1e-44

Identities = 94/94 (100%)

Strand = Plus / Plus

Query: 209 aggtatctctgaaacaaaggcagaagcatatttgtggaggaagcatcgtctcaccacagt 268

Sbjct: 47990 aggtatctctgaaacaaaggcagaagcatatttgtggaggaagcatcgtctcaccacagt 48049

Query: 269 gggtgatcacggcggctcactgcattgcaaacag 302

Sbjct: 48050 gggtgatcacggcggctcactgcattgcaaacag 48083

